A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-P2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jan 2018 According to an Eli Lilly media release, based on findings from SPIRIT-P1 and SPIRIT-P2 trials the European Commission has granted marketing authorisation (MA) for Taltz (ixekizumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
    • 01 Dec 2017 According to an Eli Lilly media release, FDA has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). The efficacy and safety of Taltz was determined from findings from two Phase 3 studies- SPIRIT-P1 and SPIRIT-P2.
    • 08 Nov 2017 Results (n=679) from SPIRIT-P1 and SPIRIT-P2 studies assessing the contribution of joint and skin improvements in the health-related quality of life (HRQoL) patients with active patients with active Psoriatic Arthritis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top